Stocks · News reference
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Dermata Therapeutics announced that its Tome skincare brand has received editorial coverage in several prominent beauty and lifestyle publications following its August 2026 commercial launch.
60 Degrees Pharmaceuticals, Inc. will host an investor webinar on November 10, 2026, to discuss its clinical progress in babesiosis and commercial expansion of its malaria prevention drug, ARAKODA.
Accuray Incorporated has approved a 1-for-40 reverse stock split of its common stock to regain compliance with Nasdaq's minimum bid price requirement.
Accuray Incorporated released its financial results for the first quarter ended September 30, 2026, highlighting growth in service revenue and improved service gross margins.
The average 12-month price target for LENZ Therapeutics, Inc. has been updated based on consensus estimates from seven analysts.
FocalTherics (EDAP TMS S.A.) announced that management will participate in three upcoming healthcare investor conferences in November and December 2026.